Provided is a near-infrared ray absorbing composition including a near-infrared absorber and a solvent, wherein the near-infrared absorber contains at least one of the following component (A) and component (B); and a compound represented by Formula (I) is contained in the component (A) or component (B) in the range of 0.001 to 10% by mass based on the total mass of the near-infrared ray absorbing composition, Component (A): a component composed of at least one of a compound represented by Formula (1) or Formula (2) with a compound represented by Formula (I) and a copper ion, Component (B): a component composed of a copper complex obtained by reaction of at least one of a compound represented by Formula (1) or Formula (2) with a compound represented by Formula (I) and a copper compound,

OP(OH).sub.3Formula (I):

##STR00001##

The present invention is directed to new pyridinone or pyrimidinone hydroxamic acid phosphates of Formula (1) and boronates of Formula (2), stereoisomers thereof;

##STR00001##

wherein Q is selected from the group consisting of P(O)(OH).sub.2, P(O)(OH)(O.sup.M.sup.+), P(O)(O.sup.M.sup.+).sub.2 and P(O)(O.sup.).sub.2M.sup.2+; M.sup.+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M.sup.2+ is a pharmaceutically acceptable divalent cation; X is CH or N; and Z is as defined herein; and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

A highly efficient and safe N-cyanation and N-phosphorylation reagent for the de novo synthesis of pharmaceutically acceptable cyclocreatine and salts was achieved using trichloroacetonitrile in lieu of highly toxic cyanogen bromide (CNBr) for generating the required cyclocreatine (CCr) intermediates, followed by highly effective N-phosphorylation through pH control using phosphoryl chloride with high conversion to the corresponding cyclocreatine phosphate (CCrP) targets. A continuous flow reactor system was engineered to improve the efficiency of the process and deliver a product with improved yield, safety, and cost efficiency.

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.